Inhaled insulin for controlling blood glucose in patients with diabetes.
Diabetes mellitus is a significant worldwide health problem, with the incidence of type 2 diabetes increasing at alarming rates. Insulin resistance and dysregulated blood glucose control are established risk factors for microvascular complications and cardiovascular disease. Despite the recognition of diabetes as a major health issue and the availability of a growing number of medications designed to counteract its detrimental effects, real and perceived barriers remain that prevent patients from achieving optimal blood glucose control. The development and utilization of inhaled insulin as a novel insulin delivery system may positively influence patient treatment adherence and optimal glycemic control, potentially leading to a reduction in cardiovascular complications in patients with diabetes.
Silverman
Bernard L
BL
Alkermes, Inc, Cambridge, MA, USA.
Barnes
Christopher J
CJ
Campaigne
Barbara N
BN
Muchmore
Douglas B
DB
D000280:Administration, Inhalation; D002318:Cardiovascular Diseases / Q000503:physiopathology; D000075202:Contraindications; D003920:Diabetes Mellitus / Q000188:drug therapy* / Q000503:physiopathology; D016503:Drug Delivery Systems; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D010353:Patient Education as Topic; D017060:Patient Satisfaction; D019518:Postprandial Period
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin